Trials Delayed Due to Covid-19 Begin to Resume
Since early March, more than 500 companies have publicly announced disruptions to their planned and...
Read More...
Focus:
-
![covid-19 vaccines]()
FDA may be risk-averse to grant emergency use for a Covid-19 vaccine; political pressure and hazy EUA standards are factors
by Reynald Castaneda in London, with additional reporting by Jennifer C Smith The FDA’s revocation of chloroquine and hydroxychloroquine’s Emergency…
Read More…
-
![remdesivir covid-19]()
Gilead’s remdesivir to commence Phase I trials as inhaled therapy to target mild Covid-19 patients
On 22 June, Gilead announced that it will begin Phase I clinical trials for inhaled remdesivir in healthy volunteers, and…
Read More…
-
![dexamethasone]()
Dexamethasone, an unexpected drug, shows promise in treating Covid-19
Currently, there are over 2,200 clinical trials trying to find a vaccine or a therapy for Covid-19. The National Institute…
Read More…
-
![covid-19 vaccines]()
CanSino’s, J&J’s Covid-19 vaccines may be stifled by pre-existing antibodies while AstraZeneca’s, ReiThera’s may need booster
by Reynald Castaneda in London. Despite its advantages over other vaccine technologies for Covid-19, adenovirus vector vaccines are likely to…
Read More…
-
![europe covid-19 clinical trials]()
The UK leads Covid-19 clinical investigations in Europe
As Europe has been significantly impacted by the Covid-19 pandemic, a substantial amount of clinical research is currently focused on…
Read More…
-
![relugolix trial]()
Myovant’s Phase III relugolix trial’s cardiovascular event reduction trend inconclusive
by Reynald Castaneda in London. Myovant Sciences’ Phase III relugolix trial in castrate-sensitive prostate cancer reporting of a positive trend in…
Read More…
-
![astrazenecas tagrisso]()
AstraZeneca’s Tagrisso divides on immediate adoption in adjuvant non-small cell lung cancer
by Manasi Vaidya in New York. AstraZeneca’s Tagrisso (osimertinib) may not find widespread adoption in the adjuvant setting for non-small cell…
Read More…
-
![mdma]()
Long-term efficacy data shows MDMA is effective for treating PTSD
The Multidisciplinary Association for Psychedelic Studies (MAPS) is developing the first-in-class innovator drug midomafetamine (MDMA) for use in treating chronic…
Read More…
-
![disrupted clinical trials]()
Clinical trial disruption due to Covid-19 has begun to slow
Since early March, hundreds of organisations that are acting as the sponsor, collaborator, or contract research organisation (CRO) have publicly…
Read More…
